Results 21 to 30 of about 4,930 (173)

Avaliação da capacidade de carga turística para gestão de praias em Moçambique: o caso da Praia do Tofo [PDF]

Revista de Gestão Costeira Integrada, 2013
Coastal zones are important areas for recreational activities and are determinants of extensive tourist flows all over the World.
D. Zacarias
openaire   +3 more sources

Reef fish communities of Praia do Tofo, Mozambique, and the need for best practice management

, 2016
The coral reefs around Praia do Tofo, southern Mozambique, are known for their aggregations of marine megafauna but as yet few studies have comprehensively examined their broader biodiversity. This study is the first to assess the ichthyofaunal diversity of this economically important area.
A. Fordyce
openaire   +2 more sources

Um Olhar para a Ética Ambiental, a partir do Modelo de Turistificação de Espaço das Praias de Tofo, Barra, Tofinho e Rocha (TBT) – Moçambique

Turismo: Visão e Ação
Objetivo – O estudo desenvolve uma análise crítica, centrada no processo de turistificação espacial da região de Tofo, Barra, Tofinho e Rocha, (Município de Inhambane), geograficamente designada pela sigla TBT, no contexto cartográfico moçambicano, a partir de uma perspectiva analítica da ética ambiental.
Tomás de Azevedo Júlio, Elimar Pinheiro do Nascimento   +1 more
openaire   +2 more sources

The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes. [PDF]

Pharmacol Res Perspect, 2022
Tofogliflozin, a highly specific SGLT2 inhibitor, suppresses atherosclerosis by improving glucose intolerance associated with inhibition of inflammation in the diabetic ApoEKO mice. Abstract Epidemiological and animal studies have revealed that sodium‐glucose cotransporter 2 (SGLT2) inhibitors suppress cardiovascular events in subjects with type 2 ...
Iwamoto M, Kubota T, Sakurai Y, Wada N, Shioda S, Yamauchi T, Kadowaki T, Kubota N.   +7 more
europepmc   +2 more sources

Evidence of Závora Bay as a critical site for reef manta rays, Mobula alfredi, in southern Mozambique. [PDF]

J Fish Biol, 2022
Abstract The largest known reef manta ray (Mobula alfredi) population in Africa has been monitored for more than 20 years at several locations on the coast of the Inhambane Province in southern Mozambique. Nonetheless, before this study, little had been reported on the population dynamics of M.
Carpenter M, Cullain N, Venables SK, Tibiriçá Y, Griffiths C, Marshall AD.   +5 more
europepmc   +2 more sources

Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. [PDF]

Diabetes Obes Metab, 2022
Diabetes, Obesity and Metabolism, Volume 24, Issue 12, Page 2469-2473, December 2022.
Matsubayashi Y, Yoshida A, Suganami H, Oe M, Sato T, Yaguchi Y, Fujihara K, Yamada T, Tanaka S, Kaku K, Sone H.   +10 more
europepmc   +2 more sources

Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin. [PDF]

Diabetes Obes Metab, 2020
Abstract Aims Obesity and hepatic fat accumulation diminish hepatic insulin clearance, which can cause hyperinsulinaemia. Sodium/glucose‐cotransporter 2 inhibitors (SGLT2‐is) improve insulin resistance and hyperinsulinaemia by weight loss via increased urinary glucose excretion in type 2 diabetes.
Matsubayashi Y, Yoshida A, Suganami H, Osawa T, Furukawa K, Suzuki H, Fujihara K, Tanaka S, Kaku K, Sone H, Sone H.   +10 more
europepmc   +2 more sources

Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss. [PDF]

Diabetes Obes Metab, 2020
Abstract Aims To investigate predictors of the initial response of beta‐hydroxybutyrate (BHB) and maximum BHB (max‐BHB) values during long‐term therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin (TOFO), and to explore the association of the initial elevation of BHB with subsequent clinical effects in people with type 2 diabetes ...
Sato Y, Nunoi K, Kaku K, Yoshida A, Suganami H.   +4 more
europepmc   +2 more sources

Reductions in liver enzymes are associated with anti-hyperglycaemic and anti-obesity effects of tofogliflozin in people with type 2 diabetes: Post-hoc analyses. [PDF]

Endocrinol Diabetes Metab
Reductions in GGT and ALT were associated with the anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin, respectively, in people with T2D. Therefore, GGT and ALT may be surrogate markers for hyperglycaemia and obesity in T2D. Abstract Aims How the pathology of type 2 diabetes (T2D), including hyperglycaemia and obesity, affects liver enzymes ...
Takamura T, Kaku K, Yoshida A, Kusakabe H, Nakamura H, Suganami H.   +5 more
europepmc   +2 more sources

Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease. [PDF]

FEBS Open Bio, 2019
Here, we demonstrate that the highly specific sodium‐glucose cotransporter 2 inhibitor (SGLT2I) prevented the progression of nonalcoholic steatohepatitis (NASH)‐related renal injury in a medaka fish model of NASH‐related kidney disease. SGLT2I ameliorates oxidative stress and macrophage accumulation and maintained mitochondrial function in renal ...
Nagoya T, Kamimura K, Goto R, Shinagawa-Kobayashi Y, Niwa Y, Kimura A, Sakai N, Ko M, Nishina H, Terai S.   +9 more
europepmc   +2 more sources